Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiomic analysis reveals that polyamines alter G. vaginalis-induced cervicovaginal epithelial cell dysfunction.

Research square·2026
Same author

Multiomic analysis reveals that polyamines alter G. vaginalis-induced cervicovaginal epithelial cell dysfunction.

bioRxiv : the preprint server for biology·2025
Same author

Cervicovaginal microbiome alters transcriptomic and chromatin accessibility signatures across cervicovaginal epithelial barriers.

Microbiome·2025
Same author

Increased formation of angiotensin II from angiotensin I in individuals of African descent.

Journal of hypertension·2025
Same author

Cervicovaginal microbiome alters transcriptomic and epigenomic signatures across cervicovaginal epithelial barriers.

Research square·2025
Same author

Fatigue loading and volumetric microscopy demonstrate changes to the mouse cervix throughout and after pregnancy.

Connective tissue research·2025

Related Experiment Video

Updated: Jun 7, 2026

Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis
05:30

Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis

Published on: November 8, 2024

Angiotensin II and angiotensin-(1-7) decrease sFlt1 release in normal but not preeclamptic chorionic villi: an in

Lauren Anton1, David C Merrill, Liomar A A Neves

  • 1Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

Reproductive Biology and Endocrinology : RB&E
|November 6, 2010
PubMed
Summary

Angiotensin peptides inhibit soluble VEGF receptor 1 (sFlt1) release in normal pregnancy. This regulation is lost in preeclampsia, potentially causing anti-angiogenesis and maternal organ damage.

More Related Videos

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas
05:31

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas

Published on: January 26, 2024

siRNA Transfection and EMSA Analyses on Freshly Isolated Human Villous Cytotrophoblasts
09:57

siRNA Transfection and EMSA Analyses on Freshly Isolated Human Villous Cytotrophoblasts

Published on: September 20, 2016

Related Experiment Videos

Last Updated: Jun 7, 2026

Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis
05:30

Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis

Published on: November 8, 2024

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas
05:31

Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas

Published on: January 26, 2024

siRNA Transfection and EMSA Analyses on Freshly Isolated Human Villous Cytotrophoblasts
09:57

siRNA Transfection and EMSA Analyses on Freshly Isolated Human Villous Cytotrophoblasts

Published on: September 20, 2016

Area of Science:

  • Reproductive biology and endocrinology
  • Maternal-fetal medicine
  • Vascular biology

Background:

  • Preeclampsia is associated with impaired placental angiogenesis, a process crucial for pregnancy health.
  • Key placental factors like VEGF, PLGF, sFlt1, and sEng regulate placental development, but their interaction with the renin-angiotensin system during pregnancy is understudied.

Purpose of the Study:

  • To investigate the impact of angiotensin II (Ang II) and angiotensin-(1-7) [Ang-(1-7)] on the release of angiogenic factors from placental chorionic villi (CV).
  • To explore potential mechanisms linking the renin-angiotensin system to angiogenic dysregulation in preeclampsia.

Main Methods:

  • Collected placental chorionic villi from normotensive and preeclamptic women in their third trimester.
  • Incubated CV with varying concentrations of Ang II or Ang-(1-7) for up to 16 hours.
  • Quantified the release of VEGF, PLGF, sFlt1, sEng, LDH, and HPL using ELISA.

Main Results:

  • sFlt1 and sEng release increased over time and were significantly higher in preeclamptic CV compared to normal CV.
  • Ang II and Ang-(1-7) significantly inhibited sFlt1 release from normal CV within 2 hours.
  • VEGF levels were below assay detection limits; HPL release confirmed CV viability.

Conclusions:

  • Angiotensin peptides play a critical role in inhibiting sFlt1 release in normal pregnancy.
  • The diminished inhibitory effect of angiotensin peptides on sFlt1 in preeclampsia may contribute to elevated sFlt1 levels, leading to anti-angiogenesis and maternal end-organ damage.